# Anemia, Sickle Cell trials: 127 new since Nov 2024

Updated November 9, 2026.

127 clinical studies in Anemia, Sickle Cell were first posted on ClinicalTrials.gov from November 14, 2024 to November 9, 2026; 19 have an industry sponsor and 99 are recruiting or about to. The newest, NCT07925372, was posted on November 9, 2026: Acute Pain Management of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease in the... (Central Hospital, Nancy, France).

## The full list

New Anemia, Sickle Cell clinical trials: 127 rows for $6.35, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/anemia-sickle-cell

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 127
- Industry sponsored: 19
- Recruiting or not yet: 99
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 127, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925372 | Acute Pain Management of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease in the Emergency Department: a Comparative... | Central Hospital, Nancy, France | Observational | Completed | Sickle Cell Disease | 92 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925372) |
| November 3, 2026 | NCT07911618 | Data Collection For Patients With Sickle Cell Disease | M.D. Anderson Cancer Center | Observational | Not yet recruiting | Data Collection, Sickle Cell Disease | 500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911618) |
| November 2, 2026 | NCT07910396 | Focused Ultrasound Neuromodulation for Chronic Pain | University of Minnesota | Not applicable | Not yet recruiting | Chronic Pain, Sickle Cell Disease, Chronic Pelvic Pain Syndrome | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910396) |
| October 23, 2026 | NCT07892651 | MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) | Axiom Bioregistry | Observational | Not yet recruiting | Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)... | 5,000 | Jordan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892651) |
| October 16, 2026 | NCT07877753 | Evolution of Sickle Cell Maculopathy | Christophe Orssaud | Observational | Completed | Sickle Cell Disease, Macula Thickening, Macula Abnormality | 34 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877753) |
| October 15, 2026 | NCT07875777 | Self-administered Acupressure in Patients With Sickle Cell Disease | University of Cincinnati | Not applicable | Not yet recruiting | Sickle Cell Disease (SCD) | 300 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875777) |
| October 8, 2026 | NCT07865039 | Inflammatory Markers and Pain in Sickle Cell Disease | Assiut University | Observational | Not yet recruiting | Sickle Cell Disease | 75 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865039) |
| October 1, 2026 | NCT07852442 | Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS... | Centre Hospitalier Universitaire de la Guadeloupe | Observational | Not yet recruiting | Sickle Cell Disease, Venous Thromboembolism | 60 | France, Guadeloupe | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852442) |
| September 18, 2026 | NCT07826988 | Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis | Assistance Publique - Hôpitaux de Paris | Phase 4 | Not yet recruiting | Sickle Cell Disease, Vaso-occlusive Crisis | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07826988) |
| September 3, 2026 | NCT07802210 | Effectiveness of Innovative Educational Methods in Empowering Children With Sickle Cell Disease | Aula Ibrahim abd alrazak | Not applicable | Not yet recruiting | Sickle Cell Anemia in Children | 120 | Iraq | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802210) |
| September 2, 2026 | NCT07800247 | Hemoglobin Disorders in Egypt: Sickle Cell Disease Ain Shams University Institutional Registry | Ain Shams University | Observational | Recruiting | Sickle Cell Disease (SCD) | 400 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800247) |
| September 2, 2026 | NCT07799571 | Buprenorphine for the Management of Pain in Children With Sickle Cell Disease | Natasha Archer | Phase 1 | Not yet recruiting | Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in... | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799571) |
| September 1, 2026 | NCT07797582 | MBI for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease | University of Illinois Chicago | Not applicable | Not yet recruiting | Chronic Pain, Sickle Cell Disease, Sleep | 48 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797582) |
| August 24, 2026 | NCT07782489 | Pleuropulmonary Ultrasound Imaging in Patients With Sickle Cell Disease in a Vaso-occlusive Crisis. "ECHODREP" | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Sickle Cell Disease (SCD), Vaso-Occlusive Crises, Acute Chest Syndrome | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782489) |
| August 20, 2026 | NCT07776444 | Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography | Washington University School of Medicine | Not applicable | Recruiting | Sickle Cell Disease, Cerebral Stroke | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776444) |
| August 7, 2026 | NCT07753681 | Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System | Centre for Infectious Disease Research in Zambia | Observational | Recruiting | Cardiac Diseases, Sickle Cell Disease, Hypertension, Diabetes Mellitus, Heart Failure, Congenital Heart Disease... | 2,084 | Zambia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753681) |
| August 7, 2026 | NCT07752043 | Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients | Assistance Publique - Hôpitaux de Paris | Not applicable | Not yet recruiting | Sickle Cell Disease (SCD), Vaso-occlusive Events | 30 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752043) |
| July 22, 2026 | NCT07721155 | Objective Neurocognitive Assessment of Young Children With Sickle Cell Disease by Eye-Tracking | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Observational | Completed | Sickle Cell Disease, Sickle Cell, Neurocognition, Child | 93 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721155) |
| July 22, 2026 | NCT07719972 | Universal Newborn Screening For Sickle Cell Disease In Mozambique | St. Jude Children's Research Hospital | Not applicable | Not yet recruiting | Sickle Cell Disease | 6,750 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719972) |
| July 16, 2026 | NCT07708714 | Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study | Children's Hospital Medical Center, Cincinnati | Phase 1/2 | Recruiting | Sickle Cell Disease, Sickle Cell Anemia in Children | 250 | Uganda | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708714) |
| July 16, 2026 | NCT07708350 | Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease | Daniel Bauer | Phase 1 | Recruiting | Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0) | 5 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708350) |
| July 14, 2026 | NCT07703566 | CPAP for Hypoxemic Acute Chest Syndrome in Sickle Cell Disease | Assistance Publique - Hôpitaux de Paris | Not applicable | Not yet recruiting | Sickle Cell Disease (SCD), Acute Chest Syndrome (ACS) | 140 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703566) |
| July 6, 2026 | NCT07682662 | Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis | University of Mississippi Medical Center | Phase 4 | Not yet recruiting | Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD) | 400 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682662) |
| June 29, 2026 | NCT07674277 | Virtual Reality for SCD VOC | University of Maryland, Baltimore | Not applicable | Recruiting | Sickle Cell Disease | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674277) |
| June 18, 2026 | NCT07656415 | A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) | Agios Pharmaceuticals, Inc. | Phase 3 | Recruiting | Sickle Cell Disease | 159 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656415) |
| June 15, 2026 | NCT07648043 | Feasibility and Acceptability of Amani | Massachusetts General Hospital | Phase 1/2 | Not yet recruiting | Sickle Cell Disease | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648043) |
| June 11, 2026 | NCT07640815 | Expanded Access Protocol for Gene Therapy Utilizing shmiR Lentivirus Vector to Induce Fetal Hemoglobin in Sickle Cell Disease | David Williams | Not applicable | Temporarily not available | Sickle Cell Disease | Not listed | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640815) |
| June 10, 2026 | NCT07639008 | Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025 | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Sickle Cell Disease (SCD), Invasive Bacterial Infections | 350 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639008) |
| June 1, 2026 | NCT07616154 | Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease | St. Jude Children's Research Hospital | Phase 2 | Recruiting | Sickle Cell Disease | 45 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616154) |
| May 27, 2026 | NCT07610239 | Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening | Makerere University | Not applicable | Recruiting | Sickle Cell Disease | 24,000 | Uganda | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610239) |
| May 20, 2026 | NCT07599176 | Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1/2 | Recruiting | Sickle Cell Disease, Beta-thalassemia | 90 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599176) |
| May 5, 2026 | NCT07566494 | Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 | Recruiting | Sickle Cell Disease, Hemolytic Anemia | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566494) |
| May 1, 2026 | NCT07562451 | Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing | Emory University | Not applicable | Recruiting | Sickle Cell Disease | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562451) |
| April 28, 2026 | NCT07554547 | Crizanlizumab Pregnancy Outcomes Intensive Monitoring | Novartis Pharmaceuticals | Observational | Completed | Sickle Cell Disease | 13 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07554547) |
| April 21, 2026 | NCT07543289 | Hydroxyurea Optimisation in Sickle Cell Disease | Ochuko Orherhe | Observational | Recruiting | Sickle Cell Disease | 100 | Nigeria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543289) |
| April 20, 2026 | NCT07540767 | Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease | Connecticut Children's Medical Center | Not applicable | Not yet recruiting | Sickle Cell Disease, Sickle Cell Anemia in Children, Sickle Cell Disease (SCD), Sickle Cell, Sickle Cell Anemia (HbSS) | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540767) |
| April 16, 2026 | NCT07532564 | Risk Factors, Costs, and Impacts of ED Boarding | University of Maryland, Baltimore | Observational | Completed | Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension... | 30,486 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532564) |
| April 15, 2026 | NCT07530965 | Omega-3-Fatty Acids in Children With Sickle Cell Disease | University of Alabama at Birmingham | Not applicable | Not yet recruiting | Sickle Cell Disease (SCD) | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07530965) |
| March 27, 2026 | NCT07498309 | Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease | University Hospital, Rouen | Phase 3 | Not yet recruiting | Vaso-Occlusive Crises, Sickle Cell Disease | 144 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07498309) |
| March 23, 2026 | NCT07488520 | Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire | Swiss Tropical & Public Health Institute | Phase 4 | Recruiting | Sickle Cell Disease (SCD) | 120 | Côte d’Ivoire | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488520) |
| March 23, 2026 | NCT07488091 | Multi Disciplinary Sickle Cell Disease Obstetrics Care Program in Ghana | University of Ghana Medical School | Not applicable | Recruiting | Sickle Cell Disease and Pregnancy | 198 | Ghana | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488091) |
| March 4, 2026 | NCT07450430 | Optimal Timing of Ketamine Initiation for SCD Pain | Boston Children's Hospital | Phase 3 | Not yet recruiting | Sickle Cell Disease, Sickle Cell Crisis | 90 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07450430) |
| March 2, 2026 | NCT07442851 | SickleFit Exercise and Nutrition Study | Duke University | Not applicable | Recruiting | Sickle Cell Disease, Aging | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07442851) |
| February 27, 2026 | NCT07436767 | Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease | Institute of Hematology & Blood Diseases Hospital, China | Not applicable | Suspended | Sickle Cell Disease | 3 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436767) |
| February 25, 2026 | NCT07432867 | Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected... | Assistance Publique - Hôpitaux de Paris | Phase 1/2 | Recruiting | Sickle Cell Disease | 15 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432867) |
| February 24, 2026 | NCT07431398 | Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease | Fulcrum Therapeutics | Phase 1 | Terminated | Sickle Cell Disease | 13 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431398) |
| February 11, 2026 | NCT07402811 | Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease | University of Illinois Chicago | Not applicable | Completed | Chronic Pain, Sickle Cell Disease, Sleep Disturbance | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07402811) |
| February 11, 2026 | NCT07401823 | Open-Label Extension Study to Pioneer Study 6058-SCD-101 | Fulcrum Therapeutics | Phase 2 | Terminated | Sickle Cell Disease | 1 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07401823) |
| February 6, 2026 | NCT07392216 | Functional Ovarian Reserve in Sickle Cell Disease | St. Jude Children's Research Hospital | Observational | Recruiting | Sickle Cell Disease | 440 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392216) |
| January 28, 2026 | NCT07373639 | A Long-term Follow-up Study in Patients Who Received BEAM-101 | Beam Therapeutics Inc. | Observational | Recruiting | Hemoglobinopathy, Sickle Cell Disease | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07373639) |
| January 27, 2026 | NCT07369024 | Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults | Mohsen Saidinejad | Phase 2 | Recruiting | Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management... | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369024) |
| January 21, 2026 | NCT07356050 | Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell... | Children's Hospital Medical Center, Cincinnati | Observational | Recruiting | Sickle Cell Disease, Measles Vaccination, Sickle Cell Anemia | 130 | Ghana, Tanzania, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356050) |
| January 14, 2026 | NCT07341022 | STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE | Hospital Israelita Albert Einstein | Phase 1/2 | Not yet recruiting | Sickle Cell Disease | 12 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341022) |
| January 5, 2026 | NCT07316478 | Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease | University of Pennsylvania | Not applicable | Recruiting | Sickle Cell Disease | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07316478) |
| December 26, 2025 | NCT07305181 | Prevalence of Abnormal Haemoglobin Variants in Metropolitan Chattogram, Bangladesh | Bangladesh Bioscience Research Group | Observational | Completed | HbE Trait, Hemoglobinopathies | 8,400 | Bangladesh | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07305181) |
| December 15, 2025 | NCT07282210 | Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype | Biossil Inc. | Phase 2 | Recruiting | Sickle Cell Disease, Sickle Cell Anaemia, Sickle Cell Anemia | 65 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282210) |
| December 11, 2025 | NCT07277023 | The Influence of micro-and Macro Vascular Dysfunction on Clinical Severity in Adults With Sickle Cell Anemia (SS) and Sickle Cell... | Centre Hospitalier Universitaire de la Guadeloupe | Not applicable | Completed | Sickle Cell Anemia | 49 | Guadeloupe | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277023) |
| December 10, 2025 | NCT07274254 | Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease | Nantes University Hospital | Phase 3 | Recruiting | Vaso-Occlusive Pain Episode in Sickle Cell Disease | 104 | France, Guadeloupe | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07274254) |
| November 26, 2025 | NCT07252050 | Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease | Arkansas Children's Hospital Research Institute | Phase 1/2 | Recruiting | Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant... | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252050) |
| November 25, 2025 | NCT07247188 | Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | Sanofi | Phase 3 | Recruiting | Sickle Cell Disease | 100 | Dominican Republic, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07247188) |
| November 24, 2025 | NCT07246265 | Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care | University Hospital, Tours | Not applicable | Recruiting | Sickle Cell Disease, Glomerular Hyperfiltration, Sickle Cell Nephropathy, Vaso-Occlusive Crises, Acute Chest Syndrome | 100 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246265) |
| November 10, 2025 | NCT07226219 | Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment, Attention Deficit/Hyperactivity Disorder (ADHD) | 72 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226219) |
| November 4, 2025 | NCT07224360 | Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) | CSL Behring | Phase 2 | Recruiting | Sickle Cell Disease | 63 | Belgium, France, Italy, Netherlands, Turkey (Türkiye), United Kingdom, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224360) |
| October 30, 2025 | NCT07222475 | Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease | Mayo Clinic | Not applicable | Recruiting | Sickle Cell Disease | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222475) |
| October 3, 2025 | NCT07206095 | Integrative Diagnosis for SCD and Other RADs | Hospital Universitari Vall d'Hebron Research Institute | Observational | Recruiting | Sickle Cell Disease, Thalassaemia, Congenital Dyserythropoietic Anemia (CDA), Enzyme Disorder; Anemia, Spherocytosis... | 200 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206095) |
| October 1, 2025 | NCT07200869 | Outcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease | Assiut University | Observational | Not yet recruiting | Sickle Cell Disease, Vaso-occlusive Crisis | 25 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07200869) |
| September 24, 2025 | NCT07190001 | YOLT-204 in Patients With Hemoglobinopathies | Guangzhou Women and Children's Medical Center | Early phase 1 | Not yet recruiting | Hemoglobinopathies (Transfusion-dependent β-thalassemia and Sickle Cell Disease) | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190001) |
| September 23, 2025 | NCT07188766 | Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis | Imam Abdulrahman Bin Faisal University | Not applicable | Recruiting | SCD, Vaso Occlussive Crisis | 394 | Saudi Arabia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07188766) |
| September 23, 2025 | NCT07187973 | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) | Disc Medicine, Inc | Phase 1 | Recruiting | Sickle Cell Disease | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07187973) |
| September 18, 2025 | NCT07180836 | Prevalence and Hematological Characteristics of Hemoglobinopathies | Bacha Khan Medical College | Observational | Completed | Hemoglobinopathies | 839 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07180836) |
| September 16, 2025 | NCT07177300 | Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) | Children's Hospital Medical Center, Cincinnati | Phase 4 | Recruiting | Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0) | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07177300) |
| September 16, 2025 | NCT07175051 | Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin | University of Illinois Chicago | Phase 2 | Recruiting | Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175051) |
| September 11, 2025 | NCT07168447 | Transfusion Exchanges and Cognition in Sickle Cell Disease | Centre Hospitalier St Anne | Observational | Not yet recruiting | Drepanocytosis, Chronic Neurological Deficiency | 85 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168447) |
| September 4, 2025 | NCT07155031 | Biotin-Acridine Red Cell Exchange Kinetics | Cerus Corporation | Phase 2 | Withdrawn | Sickle Cell Disease | 0 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07155031) |
| August 28, 2025 | NCT07145411 | HPC Offered for PRESERVE Expansion | Ossium Health, Inc. | Observational | Recruiting | Bone Marrow Transplant (BMT) | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07145411) |
| August 12, 2025 | NCT07116772 | Serial Assessment of Fertility Experiences | Children's Hospital Medical Center, Cincinnati | Observational | Recruiting | Sickle Cell Anemia | 250 | Dominican Republic, Jamaica, Tanzania | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116772) |
| July 30, 2025 | NCT07094646 | Full Assessment of Clinical Transfusion Support | Children's Hospital Medical Center, Cincinnati | Observational | Completed | Sickle Cell Anemia, Blood Transfusion, Malaria Parasitaemia | 250 | Uganda | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07094646) |
| July 29, 2025 | NCT07090668 | Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell... | Emory University | Not applicable | Recruiting | Sickle Cell Disease | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090668) |
| July 24, 2025 | NCT07083531 | Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait | UConn Health | Observational | Recruiting | Sickle Cell Disease, Sickle Cell Trait | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07083531) |
| July 15, 2025 | NCT07066072 | The Radiofrequency Therapy in Management of Sickle Cell Disease Chronic Pain RCT Tested the Effect of TECAR Therapy on Sickle Cell Disease... | Cairo University | Not applicable | Completed | the Use of Radiofrequency Ablation in Form of TECAR(Capacitive and Resistive Transfer Energy) in Chronic Pain of Sickle... | 170 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07066072) |
| July 14, 2025 | NCT07064174 | Sickle Cell Kidney Biorepository | University of Texas Southwestern Medical Center | Observational | Recruiting | Sickle Cell Trait, Sickle Cell Disease (SCD), Chronic Kidney Disease | 800 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07064174) |
| June 25, 2025 | NCT07037706 | Use of Macrolides in Acute Chest Syndrome: A Multicenter Retrospective Study | Centre Hospitalier de Saint-Denis | Observational | Completed | Sickle Cell Disease, Acute Chest Syndrome, Glucose-6-Phosphate Dehydrogenase Deficiency, Anti-Bacterial Agents... | 250 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037706) |
| June 17, 2025 | NCT07023666 | Early Screening and Treatment of Heart Complication in Sickle Cell Disease | Inova Health Care Services | Phase 2 | Recruiting | Sickle Cell Disease | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07023666) |
| June 15, 2025 | NCT07023029 | A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants | Novo Nordisk A/S | Phase 1 | Completed | Healthy Volunteers, Sickle Cell Disease, Thalassemia | 33 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07023029) |
| June 11, 2025 | NCT07015684 | 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) | Columbia University | Phase 1 | Recruiting | Sickling Disorder Due to Hemoglobin S | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07015684) |
| June 3, 2025 | NCT07001631 | Effect of EMDR for Reduction of Pain Interference in Children With Sickle Cell Disease | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not applicable | Recruiting | Sickle Cell Disease, Pain, Pain, Chronic Disease | 40 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07001631) |
| June 3, 2025 | NCT07001189 | Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients | Centre Hospitalier Universitaire de la Guadeloupe | Observational | Recruiting | Sickle Cell, Sickle Cell Disease, Vaso-Occlusive Crises | 34 | Guadeloupe | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07001189) |
| June 3, 2025 | NCT07000747 | Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients | Centre Hospitalier Universitaire de la Guadeloupe | Observational | Recruiting | Dengue (Virus); Fever, Sandfly, Sickle Cell Disease | 130 | Guadeloupe | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07000747) |
| June 2, 2025 | NCT07000318 | CS-206 in Patients With Sickle Cell Disease | Children's Hospital of Fudan University | Early phase 1 | Not yet recruiting | Sickle Cell Disease | 5 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07000318) |
| May 25, 2025 | NCT06989567 | A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute... | Asklepion Pharmaceuticals, LLC | Phase 3 | Not yet recruiting | Sickle Cell Disease | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06989567) |
| May 23, 2025 | NCT06986837 | Role of Inflammasome in Platelet Activation in Sickle Cell Disease Patient | Centre Hospitalier Universitaire de la Guadeloupe | Observational | Completed | Sickle Cell Disease | 92 | Guadeloupe | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06986837) |
| May 20, 2025 | NCT06979492 | Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease | Emory University | Phase 4 | Withdrawn | Sickle Cell Disease, Pregnancy Related | 0 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06979492) |
| May 16, 2025 | NCT06975865 | The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease | Sanofi | Phase 3 | Recruiting | Sickle Cell Disease | 192 | Belgium, Brazil, France, Germany, Greece, Israel, Italy, Netherlands, Oman... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975865) |
| April 25, 2025 | NCT06944067 | Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease | National Human Genome Research Institute (NHGRI) | Observational | Recruiting | Sickle Cell Disease | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06944067) |
| April 23, 2025 | NCT06941389 | Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric... | University of Rochester | Observational | Recruiting | Sickle Cell Disease (SCD) | 480 | Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06941389) |
| April 23, 2025 | NCT06939933 | Effect of Aquatic Exercises on Muscle Strength and Quality of Life in Children With Sickle Cell Anemia | Kafrelsheikh University | Not applicable | Completed | Sickle Cell Anemia in Children | 50 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06939933) |
| April 16, 2025 | NCT06930703 | Cannabidiol in Sickle Cell Disease | Icahn School of Medicine at Mount Sinai | Phase 1/2 | Recruiting | Sickle Cell Disease | 52 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06930703) |
| April 13, 2025 | NCT06924970 | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) | Agios Pharmaceuticals, Inc. | Phase 2 | Active not recruiting | Sickle Cell Disease | 59 | Belgium, Canada, France, Ireland, Netherlands, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06924970) |
| April 11, 2025 | NCT06923111 | PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease \[PRECISE PASS\] | Nova Laboratories Limited | Observational | Recruiting | Sickle Cell Disease | 180 | Germany, United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06923111) |
| April 9, 2025 | NCT06919224 | Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease | Ohio State University | Not applicable | Recruiting | Sickle Cell Disease | 287 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06919224) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Assistance Publique - Hôpitaux de Paris | 9 | September 18, 2026 |
| Centre Hospitalier Universitaire de la Guadeloupe | 6 | October 1, 2026 |
| St. Jude Children's Research Hospital | 5 | July 22, 2026 |
| Children's Hospital Medical Center, Cincinnati | 5 | July 16, 2026 |
| University of Illinois Chicago | 4 | September 1, 2026 |
| Emory University | 4 | May 1, 2026 |
| Hospital Universitari Vall d'Hebron Research Institute | 3 | October 3, 2025 |
| University of Cincinnati | 2 | October 15, 2026 |
| Assiut University | 2 | October 8, 2026 |
| Washington University School of Medicine | 2 | August 20, 2026 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2 | July 22, 2026 |
| University of Maryland, Baltimore | 2 | June 29, 2026 |
| Agios Pharmaceuticals, Inc. | 2 | June 18, 2026 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 | May 20, 2026 |
| Fulcrum Therapeutics | 2 | February 24, 2026 |
| Sanofi | 2 | November 25, 2025 |
| CSL Behring | 2 | November 4, 2025 |
| Cairo University | 2 | July 15, 2025 |
| Centre Hospitalier de Saint-Denis | 2 | June 25, 2025 |
| University Hospital, Toulouse | 2 | March 20, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 43 | November 2, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 42 | November 9, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 11 | June 1, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 8 | September 2, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 8 | June 18, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 7 | July 16, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 5 | September 18, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 2 | September 24, 2025 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 1 | January 7, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 62 | November 3, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 21 | November 9, 2026 |
| [Guadeloupe](https://specstream.ai/data/clinical-trials/country/guadeloupe) | 7 | October 1, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 6 | October 8, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 6 | July 22, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 6 | November 4, 2025 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 4 | December 15, 2025 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 4 | October 3, 2025 |
| [Uganda](https://specstream.ai/data/clinical-trials/country/uganda) | 3 | July 16, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 3 | February 27, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 3 | November 4, 2025 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 3 | November 4, 2025 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 3 | November 4, 2025 |
| [Ghana](https://specstream.ai/data/clinical-trials/country/ghana) | 2 | March 23, 2026 |
| [Tanzania](https://specstream.ai/data/clinical-trials/country/tanzania) | 2 | January 21, 2026 |
| [Dominican Republic](https://specstream.ai/data/clinical-trials/country/dominican-republic) | 2 | November 25, 2025 |
| [Saudi Arabia](https://specstream.ai/data/clinical-trials/country/saudi-arabia) | 2 | September 23, 2025 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 2 | May 16, 2025 |
| [Jordan](https://specstream.ai/data/clinical-trials/country/jordan) | 1 | October 23, 2026 |
| [Iraq](https://specstream.ai/data/clinical-trials/country/iraq) | 1 | September 3, 2026 |
| [Zambia](https://specstream.ai/data/clinical-trials/country/zambia) | 1 | August 7, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 1 | April 28, 2026 |
| [Nigeria](https://specstream.ai/data/clinical-trials/country/nigeria) | 1 | April 21, 2026 |
| [Côte d’Ivoire](https://specstream.ai/data/clinical-trials/country/c-te-d-ivoire) | 1 | March 23, 2026 |
| [Bangladesh](https://specstream.ai/data/clinical-trials/country/bangladesh) | 1 | December 26, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).